Release this Report to Investors

Via Email

Via Text


If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us

We are excited to present Otsuka Holdings Co. Ltd. (OTC: OTSKF).

Full DD Report for OTSKF

Recent News from (OTC: OTSKF)

Books will close today December 29, 2017.
Books will close today December 29, 2017.
Source: OTC Markets
Date: December, 29 2017 00:00
Otsuka teams up with X-Chem in drug discovery
Otsuka Holdings ( OTCPK:OTSKF )( OTCPK:OTSKY ) unit Otsuka Pharmaceutical inks an agreement with privately held X-Chem aimed at advancing Otsuka drug compounds. More news on: Otsuka Holdings Co. Ltd., Otsuka Holdings Co. Ltd. ADR, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: December, 19 2017 16:10
Otsuka bails on Sativex, returns rights to GW Pharma
GW Pharmaceuticals ( GWPH +0.7% ) and Otsuka Pharmaceutical ( OTCPK:OTSKF )( OTCPK:OTSKY ) terminate their license agreement for cannabinoid Sativex (nabiximols), returning the U.S. rights to GW who has agreed to pay Otsuka milestone payments upon FDA approval and the achievement of cert...
Source: SeekingAlpha
Date: December, 13 2017 10:29
U.S. Regulators Approve Digital Pill That Tracks When People Take It
That’s one small step for man, one giant leap for healthcare and technology. On Tuesday, the FDA announced that it has approved the first digital pill that has a sensor to track if patients are taking their medication properly. Essentially, the digital pill is a version of Otsuka Pharma...
Source: StreetSignals
Date: November, 14 2017 16:30
Your Daily Pharma Scoop: Teva Q3 Results, Boost For RedHill, Clovis Reports Rubraca Sales
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Please click here or scroll down below to read an important announcement about chan...
Source: SeekingAlpha
Date: November, 02 2017 09:42
Mylan partners with Otsuka to commercialize tuberculosis med delamanid in high-burden countries
Subsidiaries of Mylan N.V. (NASDAQ: MYL ) and Otsuka Pharmaceutical Co. ( OTCPK:OTSKY )( OTCPK:OTSKF ) ink an agreement to commercialize delamanid, branded as Deltyba by Otsuka, for the treatment of adults with pulmonary multidrug-resistant tuberculosis in low- and middle-income countries....
Source: SeekingAlpha
Date: August, 24 2017 07:09
FDA to review marketing application for antidepressant drug-device combo
Otsuka Pharmaceutical ( OTCPK:OTSKF )( OTCPK:OTSKY ) resubmits its New Drug Application (NDA) to the FDA seeking approval of a drug-device combination of antidepressant ABILIFY (aripiprazole) embedded with an ingestible sensor made by Proteus Digital Health (Private: PRDI ) in a single...
Source: SeekingAlpha
Date: May, 23 2017 10:07
Teva out-licenses migraine candidate fremanezumab to Otsuka for $50M
Teva Pharmaceutical Industries ( TEVA +0.3% ) inks an agreement with Otsuka Pharmaceutical Co. ( OTCPK:OTSKF )( OTCPK:OTSKY ) granting the latter exclusive rights to develop and commercialize fremanezumab (TEV-48125) in Japan for the prevention of migraine. More news on: Teva Pharmaceu...
Source: SeekingAlpha
Date: May, 15 2017 09:51
NetworkNewsBreaks - Akebia Therapeutics, Inc. (NASDAQ: AKBA) Remains Focused on Further Development of Vadadustat
Akebia Therapeutics (NASDAQ: AKBA) is a biopharmaceutical company engaged in discovering and developing novel therapeutic solutions that leverage hypoxia inducible factor (HIF) biology, a primary regulator involved in multiple major biological pathways. According to an earlier Aegis report ( h...
Source: NetworkNewsWire
Date: January, 25 2017 09:30
Medtechs Flock To London As 2016 Sees Biggest IPO Ever
Had it not been for Convatec (CNVVY) last year would have been quiet on the IPO markets, albeit with a slight improvement in the later months. The UK company pulled off the largest IPO in the medical technology sector’s history, with its former owners raising £1.4bn ($1.9bn) listin...
Source: SeekingAlpha
Date: January, 20 2017 11:33


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report.

About Otsuka Holdings Co. Ltd. (OTC: OTSKF)

Logo for Otsuka Holdings Co. Ltd. (OTC: OTSKF)

Not available


Contact Information



Current Management

  • Tatsuo Higuchi / President, CEO

Current Share Structure

  • Market Cap: $27,713,272,608 - 03/12/2018
  • Issue and Outstanding: 557,835,600 - 11/30/2011


Recent Filings from (OTC: OTSKF)

Post-effective amendment to a previously filed F-6
Filing Type: F-6 POSFiling Source: edgar
Filing Date: September, 29 2017


Daily Technical Chart for (OTC: OTSKF)

Daily Technical Chart for (OTC: OTSKF)

Stay tuned for daily updates and more on (OTC: OTSKF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: OTSKF)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

The Subway Trader



Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in OTSKF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $0 from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of OTSKF and does not buy, sell, or trade any shares of OTSKF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by The Subway Trader. All rights reserved. Our Full Disclaimer: